Arie Belldegrun - 12 Jan 2022 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role
Director
Signature
/s/ Veer Bhavnagri, Attorney-in-Fact
Issuer symbol
ALLO
Transactions as of
12 Jan 2022
Net transactions value
+$1,953,491
Form type
4
Filing time
14 Jan 2022, 11:02:48 UTC
Previous filing
28 Mar 2022
Next filing
01 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALLO Common Stock Purchase $1,953,491 +155,039 +388% $12.60 195,039 12 Jan 2022 See footnote F1, F2
holding ALLO Common Stock 371,883 12 Jan 2022 Direct
holding ALLO Common Stock 1,798,163 12 Jan 2022 See footnote F3
holding ALLO Common Stock 4,710,148 12 Jan 2022 See footnote F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported securities were purchased by Bellco Legacy LLC at an average price of $12.60 per unit, calculated from the price range of $12.35 to $13.00.
F2 The securities are held in the name of Bellco Legacy LLC. Bellco Legacy LLC is owned and managed by trusts controlled by the reporting person and Rebecka Belldegrun.
F3 The securities are held by Vida Ventures LLC (Vida), of which VV Manager LLC is the manager. The reporting person is a Senior Managing Director of VV Manager LLC and may therefore be deemed to be the beneficial owner of the common shares held by Vida. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F4 The securities are held in the name of Bellco Legacy IV LLC, of which the reporting person and Rebecka Belldegrun are the managers.